In this study, Caco-2 permeability results from different laboratories were compared. Six different sets of apparent permeability coefficient (P app ) values reported in the literature were compared to experimental P app obtained in our laboratory. The differences were assessed by determining the root mean square error (RMSE) values between the datasets, which reached levels as high as 0.581 for the training set compounds, i.e. ten compounds with known effective human permeability (P eff ). The consequences of these differences in P app for prediction of oral drug absorption were demonstrated by introducing the P app into the absorption and pharmacokinetics simulation software application GastroPlus TM for prediction of the fraction absorbed (F a ) in humans using calibrated ''user-defined permeability models". The RMSE were calculated to assess the differences between the simulated F a and experimental values reported in the literature. The RMSE for F a simulated with the permeability model calibrated using experimental P app from our laboratory was 0.128. When the calibration was performed using P app from literature datasets, the RMSE values for F a were higher in all cases except one. This study shows quantitative lab-to-lab variability of Caco-2 permeability results and the potential consequences this can have in the use of these results for predicting intestinal absorption of drugs.
Introduction
The extent of gastro-intestinal absorption is one of the key properties for drugs intended for oral administration [1] [2] [3] [4] [5] [6] . Of many factors that govern intestinal absorption of a compound, permeability is often tested in vitro by means of cell-based assays such as the Caco-2 assay [2] [3] [4] [5] [6] [7] [8] . While the Caco-2 assay is the gold standard for in vitro permeability assessment, interpretation of the results from such assays needs careful attention due to high labto-lab variability [6, 8] .
This variability can be attributed to factors such as cell passage number, cell culture conditions, number of cells, cell monolayer integrity, etc., and can potentially mislead decisions if permeability results from different laboratories are directly compared [6] . The lab-to-lab variability itself is a known phenomenon in the field, but the extent of variability and the consequences of direct comparison of results from different laboratories have not been explicitly shown before. Therefore, the aim of this study is to compare Caco-2 permeability results between different laboratories and to evaluate potential implications of the direct use of permeability results from different laboratories for predicting oral drug absorption.
Materials and methods

Materials
Caco-2 cells of passage number 47 were purchased from Cell Culture Collections, Public Health England (Salisbury, UK). Dulbecco's modified eagle medium (DMEM) supplemented with GlutaMAX TM , 4.5 g/L D-glucose and 25 mM 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES) was purchased from Gibco (Paisley, UK 
Caco-2 permeability assay
On the day of the experiment, the Caco-2 monolayers were washed twice with transport buffer (HBSS buffer supplemented with 10 mM HEPES and pH adjusted to 7.4 using HCl or NaOH). The cells were then allowed to equilibrate for 30 min at 37°C with the transport buffer. Donor solutions were prepared to yield 50 or 200 lM of the test compound. The assay was initiated by addition of the donor solution (300 lL) at the apical side of the monolayer.
One mL of transport buffer was initially added at the basolateral side of the monolayer and 350 lL were withdrawn every 30 min up to 2 h. Fresh transport buffer (350 lL) was replaced at every sampling time point. At the end of the assay, TEER was measured again to assess the effect of compounds on the monolayers. All experiments were performed in triplicate.
Sample analysis
Samples were analysed for pravastatin using previously reported LC-MS/MS method [9] . All other compounds were analysed using an HPLC-UV system, which consisted of a Waters 600 Pump, Waters 717 Autosampler and Waters 2996 Photodiode Array Detector. A column oven was used to maintain the column temperature at 40°C. Mobile phase was a mixture of acetonitrile and 10 mM ammonium acetate buffer with pH adjusted to 4.1 with glacial acetic acid. Specific HPLC-UV conditions are listed in Table 1 .
For sample preparation, liquid-liquid extraction was applied (specific details are listed in Table 1 ). To 300 lL sample, 500 lL of pH modifier and 2 mL of extraction solvent were added. The samples were then vortex-mixed for 10 min and centrifuged at 1160 g for 10 min. The organic layer was transferred and evaporated to dryness under N 2 gas at 40°C. Reconstitution solvent Tablet  Chlorpromazine  50  Tablet  Diclofenac  50  Tablet  Piroxicam  20  Capsule  Cetirizine  10  Tablet  Cimetidine  100  Tablet  Pravastatin 40 Tablet (100 lL) was then added and vortex-mixed for 10 min before being transferred to HPLC vial for analysis.
Determination of apparent permeability coefficient
The apparent permeability coefficient (P app ) was calculated using the following equation:
where dQ/dt represents the steady-state flux (lmol/s), A represents the effective filter area of each well (cm 2 ) and C 0 represents the initial concentration of the donor solution (lM) [8] .
In silico simulation
In silico simulation of fraction absorbed in humans (F a ) was performed using GastroPlus TM version 9.0.0007. The physicochemical properties were used as predicted by the built-in ADMET Predictor TM version 7.2.0.0. Built-in pharmacokinetic model parameters for a 30 year-old American male were used as default settings, and ''Human -Physiological -Fasted" settings were applied for the gut physiology. Paracellular permeability was turned on and log D model was set as Structure-based version 6.1.
P app values of compounds with known P eff (training set compounds) were used as an input to calibrate the permeability model in GastroPlus TM and as a result a ''user-defined permeability model" was established. The same permeability value can result in different simulation results depending on how the ''user-defined permeability model" is determined. Therefore establishing a ''userdefined permeability model" represents calibrating the permeability model. In other words, the ''user-defined permeability model" plays a role as a calibration curve that can correlate P app values to P eff values. A detailed description of the ''user-defined permeability model" in GastroPlus TM could be found in the Supplementary material. The training set compounds included antipyrine, furosemide, hydrochlorothiazide, ketoprofen, metoprolol, naproxen, propranolol, ranitidine, terbutaline and verapamil. P app values from our laboratory and also the results from six different sets of literature values were used to produce seven ''user-defined permeability models". Log-linear model was selected for all datasets as it was the one suggested by GastroPlus TM after solving the correlation for all datasets.
The experimental P app values of application set compounds (desipramine, dexamethasone, sildenafil, chlorpromazine, diclofenac, piroxicam, cetirizine, cimetidine and pravastatin) obtained from our laboratory were then applied for F a simulation in GastroPlus TM . For each compound, all input parameters were fixed and only the ''user-defined permeability model" was changed for each simulation. Each P app value of the application set compounds obtained from this study was applied to the seven different ''userdefined permeability models" and human effective permeability (P eff ) values were separately predicted. These P eff values were then used to simulate seven different F a values for each compound. All other physicochemical input parameters except permeability were used as predicted by the ADMET Predictor TM . Other input parameters such as particle size, precipitation time, etc., were used as provided by default. The dose and formulation used for simulation are shown in Table 2 .
Statistical analysis
Root mean square error (RMSE) was calculated to assess the discrepancies between datasets. RMSE was normalised by the range of each dataset so that it is always between 0 and 1. 
Results and discussion
Permeability assay
The P app values obtained from the permeability study in our laboratory are listed in Table 3 . Human P eff or F a values plotted against Caco-2 P app values from our laboratory are shown in Fig. 1 . These trends in Fig. 1 are in agreement with previously reported results [1] [2] [3] [4] 7] . However, substantial differences were found across the datasets from different laboratories for absolute P app values for each individual compound (Table 3 ). This was demonstrated by the RMSE value, which was as high as 0.581 between the P app values in our laboratory and Irvine et al. In this particular case, the P app of antipyrine was different by as much as 13.3-fold. Therefore it is clear that Caco-2 permeability results (P app ) should not be directly compared across different laboratories.
Simulation of F a
In order to demonstrate the potential consequence of directly comparing P app values across laboratories, F a was simulated using GastroPlus TM for the application set compounds ( Table 4 ). The simulation was performed by applying the P app values obtained from our laboratory to permeability models calibrated with different datasets. The RMSE values were calculated to assess the differences between the simulated F a values and F a values reported in the literature. The RMSE for F a of the application set compounds simulated after calibration using P app of the training set compounds from our laboratory was 0.128. When calibration using P app of the training set compounds from other literature datasets were applied, the RMSE values for F a across all of the application set compounds were higher in all except one case (0.119-0.275). Based on these high RMSE values, it can be seen that direct comparison of Caco-2 permeability results measured experimentally to those reported by a different laboratory can mislead interpretation and the subsequent predictions.
The RMSE values were further analysed according to biopharmaceutical classification system (BCS) classes (Fig. 2) . BCS class 3 compounds showed higher RMSE values than class 1 or 2, indicating that permeability-limited compounds can be more sensitive to the lab-to-lab variability. Additionally, it should be stressed that P app values of known compounds (such as those in the training set) have to be evaluated before any permeability assessment can be made from a particular experimental setting. The literature dataset of Kerns et al. was an exception, where the RMSE was lower (0.119) than for the experimental results obtained in our laboratory.
In conclusion, Caco-2 cell permeability results for the same compounds can differ substantially between different laboratories. This variability can be caused by multiple factors related to the experimental setup of the assay including passage numbers, cell seeding density, monolayer formation period, TEER achieved and transport buffer used. Specific experimental setups used in different laboratories are summarised in Table 5 . The experimental differences in permeability can be critical, especially when it comes to application of these results, such as prediction of F a . This study shows quantitative lab-to-lab variability of Caco-2 permeability results and the potential consequences this can have in application of these results in predicting intestinal absorption of drugs. 
